Modernizing Care of Patients With BCC: Changes in Management Approaches
Supported by an unrestricted educational grant from Regeneron Pharmaceuticals.
This “Test and Teach” format consists of questions covering all aspects of the curriculum, which focuses on advanced basal cell carcinoma (BCC) assessment and management for dermatologists and oncologists.
This certified CME activity is designed for dermatologists (including Mohs surgeons), dermatology physician assistants and nurse practitioners, and oncologists involved in the care of patients with BCC.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education, LLC (Evolve)
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this Other (Blended Live and Enduring Curriculum) activity (Gather-ed Curriculum) for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistant Continuing Education
PAs may claim a maximum of 3.0 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
TO OBTAIN CREDIT
Credit will be awarded at the completion of the curriculum, after completing the Post Gathered Assessment. Credit is provided through August 30, 2022. In the event you have questions about this activity or are unable to retrieve the certificate, please email firstname.lastname@example.org.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Anthony M. Rossi, MD, FAAD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Allergan. Consultant: Almirall, Biofrontera, Canfield Scientific, Dynamed, Evolus, Lam Therapeutics, Merz, Quantia MD, and Regeneron Pharmaceuticals. Grant/Research Support: Biofrontera, Leo Pharma, and Regeneron Pharmaceuticals. Speaker’s Bureau: Almirall and Biofrontera.
Vernon K. Sondak, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: BMS, Eisai, Merck, Novartis, Regeneron Pharmaceuticals, and Replimune. Grant/Research: Neogene Therapeutics.
The Evolve staff, planners, and peer reviewers have no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals.